Current Drug Targets
Volume 22, 17 Issues, 2021
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
Current Drug Targets, Volume 17 - Number 6
Editorial Open Access
Editorial Open Access
CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses
, 17(6): 619 - 629Marion H. Brown
DOI: 10.2174/1389450116666150825120536
CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses
, 17(6): 630 - 639Rita F. Santos, Liliana Oliveira and Alexandre M. Carmo
DOI: 10.2174/1389450116666150531152439
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses
Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
, 17(6): 640 - 650Adelaida Sarukhan, Mario Martinez-Florensa, Cristina Escoda-Ferran, Esther Carrasco, Esther Carreras and Francisco Lozano
DOI: 10.2174/1389450116666150316224308
Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
, 17(6): 651 - 665David M. Kofler, Aron Farkas, Michael von Bergwelt-Baildon and David A. Hafler
DOI: 10.2174/1389450117666160201105934
The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
, 17(6): 666 - 677Patricia Hernández, Ernesto Moreno, Lazaro E. Aira and Pedro C. Rodríguez
DOI: 10.2174/1389450117666160201114308
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy
, 17(6): 678 - 692Sundararaj Stanley Jeremiah, Kenji Ohba and Naoki Yamamoto
DOI: 10.2174/138945011706160324125824
Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy
Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
, 17(6): 693 - 701Maria J. Alvarez-Cubero, Fernando Vázquez-Alonso, Ignacio Puche-Sanz, F. Gabriel Ortega, M. Martin-Prieto, José L. Garcia-Puche, Manrique Pascual-Geler, José A. Lorente, José M. Cozar-Olmo and Maria J. Serrano
DOI: 10.2174/1389450116666150309121346
Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria
, 17(6): 702 - 719Yinhu Wang, Henrietta Venter and Shutao Ma
DOI: 10.2174/1389450116666151001103948
Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria
Advances in Hyaluronic Acid-Based Drug Delivery Systems
, 17(6): 720 - 730Yan Jiao, Xin Pang and Guangxi Zhai
DOI: 10.2174/1389450116666150531155200
Advances in Hyaluronic Acid-Based Drug Delivery Systems
New Antimicrobial Approaches: Reuse of Old Drugs
, 17(6): 731 - 738Dianella Savoia
DOI: 10.2174/1389450116666150806124110
New Antimicrobial Approaches: Reuse of Old Drugs
Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
, 17(6): 739 - 745David M. Straughan, Sa d C. Azoury and Vivek Shukla
DOI: 10.2174/1573399811666150615144336
Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Editor-in-Chief
Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
(USA)
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Drug Targets Journal was launched in 2000. Dr. Francis J. Castellino serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.63
Advertisement
Webmaster Contact: info@benthamscience.net